Literature DB >> 17473450

Preventive effect of trimidox on oxidative stress in U937 cell line.

Syu-Ichi Kanno1, Mai Kakuta, Yasue Kitajima, Yuu Osanai, Kaori Kurauchi, Takaharu Ohtake, Mayuko Ujibe, Kouji Uwai, Mitsuhiro Takeshita, Masaaki Ishikawa.   

Abstract

Trimidox (3,4,5-trihydroxybenzamidoxime) is one of the most potent ribonucleotide reductase inhibitors, revealing an antitumor effect in several experimental studies. We have examined the effect of trimidox on the induction of cytotoxicity and apoptosis via oxidative stress by typical free radical inducers, hydrogen peroxide (H(2)O(2)), tert-butylhydroperoxide (tBuOOH) or ultraviolet (UV) irradiation in a human diffuse histiocytic lymphoma U937 cell line. Trimidox showed strong radical scavenging activity by the DPPH reduction assay. The 50% rate inhibited the DPPH reduction concentration of trimidox, and its derivates didox, or gallic acid were 8.8 microM, 117.5 microM, or 41.8 microM, respectively. Induction of cytotoxicity by H(2)O(2) (500 microM) or tBuOOH (100 microM) was concentration-dependently attenuated by incubation with Trimidox (10-150 microM). Trimidox also prevented the effect of UV-induced apoptosis estimated by both nuclear morphological change and DNA fragmentation. This effect was due to inhibition of the production of reactive oxygen species. Moreover, the activity and mRNA expression of catalase, an antioxidant enzyme, was significantly increased by trimidox. These results indicate that trimidox has radical scavenging activity and prevents exogenous oxidative stress and increase in catalase; therefore, trimidox is suggested as an anticancer agent exhibiting potent antioxidant properties in this study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473450     DOI: 10.1248/bpb.30.994

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

1.  Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).

Authors:  P Heffeter; A Popovic-Bijelic; P Saiko; R Dornetshuber; U Jungwirth; N Voevodskaya; D Biglino; M A Jakupec; L Elbling; M Micksche; T Szekeres; B K Keppler; A Gräslund; W Berger
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

2.  Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.

Authors:  Syu-Ichi Kanno; Naoyuki Maeda; Ayako Tomizawa; Shin Yomogida; Tadashi Katoh; Masaaki Ishikawa
Journal:  Int J Oncol       Date:  2012-06-06       Impact factor: 5.650

3.  Didox and resveratrol sensitize colorectal cancer cells to doxorubicin via activating apoptosis and ameliorating P-glycoprotein activity.

Authors:  Sahar A Khaleel; Ahmed M Al-Abd; Azza A Ali; Ashraf B Abdel-Naim
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.